---
title: "Guggenheim Reaffirms Their Buy Rating on Veracyte (VCYT)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294705162.md"
description: "Guggenheim analyst Subbu Nambi reaffirmed a Buy rating on Veracyte (VCYT) with a $65 price target. Piper Sandler also issued a Buy rating, while Canaccord Genuity maintained a Hold rating."
datetime: "2026-08-03T13:56:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294705162.md)
  - [en](https://longbridge.com/en/news/294705162.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294705162.md)
---

# Guggenheim Reaffirms Their Buy Rating on Veracyte (VCYT)

Guggenheim analyst Subbu Nambi reiterated a Buy rating on Veracyte on July 31 and set a price target of $65.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Nambi covers the Healthcare sector, focusing on stocks such as Guardant Health, Tempus AI, Inc. Class A, and Illumina. According to TipRanks, Nambi has an average return of 29.5% and a 65.94% success rate on recommended stocks.

In addition to Guggenheim, Veracyte also received a Buy from Piper Sandler’s David Westenberg in a report issued on July 31. However, today, Canaccord Genuity maintained a Hold rating on Veracyte (NASDAQ: VCYT).

### Related Stocks

- [VCYT.US](https://longbridge.com/en/quote/VCYT.US.md)
- [GH.US](https://longbridge.com/en/quote/GH.US.md)
- [TEM.US](https://longbridge.com/en/quote/TEM.US.md)
- [ILMN.US](https://longbridge.com/en/quote/ILMN.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)

## Related News & Research

- [Veracyte (VCYT) Is Down 18.2% After Raising 2026 Revenue Guidance on New Cancer Tests](https://longbridge.com/en/news/294746901.md)
- [Veracyte: Strong Earnings Beat, Raised Guidance and Emerging Diagnostics Portfolio Support Durable Upside, Justifying Buy Rating](https://longbridge.com/en/news/294488048.md)
- [Truist Financial Keeps Their Buy Rating on Kinetik (KNTK)](https://longbridge.com/en/news/295875620.md)
- [Goldman Sachs Reaffirms Their Buy Rating on Orsted (DOGEF)](https://longbridge.com/en/news/295887269.md)
- [RBC Capital Reaffirms Their Buy Rating on ABN AMRO Group N.V. (0RDM)](https://longbridge.com/en/news/295872194.md)